Mark G. Frattini

Oncology
161 Fort Washington Ave
New York, NY 10032

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

Corrigendum to: Antiproliferative Activity of Cephalotaxus Esters: Overcoming Chemoresistance.

Corrigendum to: Antiproliferative Activity of Cephalotaxus Esters: Overcoming Chemoresistance.

Journal: Combinatorial chemistry & high throughput screening
Published: January 14, 2026

Antiproliferative Activity of Cephalotaxus Esters: Overcoming Chemoresistance.

Antiproliferative Activity of Cephalotaxus Esters: Overcoming Chemoresistance.

Journal: Combinatorial chemistry & high throughput screening
Published: April 27, 2024

CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.

CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.

Journal: Leukemia research
Published: June 15, 2022

A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome.

A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome.

Journal: Journal of cancer research and clinical oncology
Published: February 02, 2022

Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.

Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 19, 2021

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

Journal: The Lancet. Oncology
Published: June 18, 2021

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 29, 2020

A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.

A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.

Journal: Blood advances
Published: October 26, 2020

Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.

Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.

Journal: Leukemia & lymphoma
Published: October 12, 2020

Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.

Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 06, 2020

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.

Journal: Cancer medicine
Published: June 15, 2020

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.

Journal: Blood
Published: June 02, 2020
Showing 1-12 of 32

Last Updated: 09/26/2026